Key Highlights
- Nexalis settled the LFO Facility by deed, with no amounts repayable and LFO's security over company Assets released.
- A deed of settlement with iNGENū CRO is in draft form, and the company expects to update the market within days.
- The company prepared a draft Phase 2 protocol for IRX-616a and obtained quotes from clinical sites and CROs.
- Cash of A$371,000 was held at 30 September 2026, with clinical development costs of A$202,000 in the quarter.
Nexalis Therapeutics Ltd (ASX:NX1) released its quarterly activities report and operations update on 30 October 2026, covering the period ended 30 September 2026. The report is focused on resolving legacy matters, including a funding facility that the company terminated in August 2026, and on preparing its IRX-616a and IRX-211 programmes for a restart once funding is in place. The company also reported a change in its non-executive chairman after the quarter.
Resolution of the LFO Facility
On 27 August 2026, the company executed a settlement deed with Linlithgow Family Office (LFO), terminating the LFO Facility by mutual agreement. The company stated that no amounts are repayable, that LFO's security over its assets has been released and that the parties have given mutual releases of all claims connected with the facility. The announcement describes the agreement as a settlement of a dispute that had been a source of uncertainty for the company.
The company said that, with the release of LFO's security on the Personal Property Securities Register, it can now progress forward funding of its Research and Development Tax Incentive refund. Work with RSM and forward financing partners is advancing toward a letter of comfort covering the period from 1 January to 30 September 2026.
The announcement presents the LFO settlement as a removal of an uncertainty for the company. It states that the settlement avoids the cost and distraction of a potential dispute and leaves the Balance Sheet free of Debt associated with the facility. The company said it is now in a position to pursue RDTI forward funding without the constraints of LFO's security interest.
Clinical Programmes and the iNGENū Settlement
Study orders with iNGENū CRO remained paused following the Withdrawal of LFO funding in May 2026. A deed of settlement with iNGENū is in draft form, and its execution would allow the close-out of the IRX-616a Phase 1 study. The company said the Phase 1 data are clean and in hand, and that a draft Phase 2 protocol has been prepared with quotes from clinical sites and CROs.
For IRX-211, the company renegotiated site terms directly with sites and vendors. Genesis Care and the South West Sydney site agreed to reduced costs, which the company said provides a viable path forward for the Phase 2 trial.
The report describes the IRX-616a Phase 1 data as clean and in hand, and the company's preparation of a Phase 2 protocol means that a study can proceed quickly once funding is secured. The company's statement that the Phase 2 study is planned and costed indicates that the next step depends on Capital rather than on study design.
Board Change and Cash Position
Sean Williams stepped down as non-executive chairman effective 2 October 2026, and Niv Dagan was appointed to the role. Nexalis held cash of A$371,000 at 30 September 2026. Quarterly spending comprised A$202,000 of clinical development costs and A$181,000 of general corporate and administration costs. No funding was received under the LFO Facility during the quarter.
Sector Context and Risks to Watch
Clinical-stage biotechnology companies typically depend on external funding to run Phase 2 studies, and the report notes that the company's clinical activity was limited during the quarter because study orders with iNGENū were paused after LFO's funding was withdrawn in May 2026. Timing of clinical programmes is therefore linked to the financing and the settlement with iNGENū.
The main risks named in the announcement are the execution of the iNGENū settlement deed, which was still in draft, the completion of the RDTI forward funding arrangements and the company's ability to secure funding for the Phase 2 study. The company's cash balance of A$371,000 at 30 September 2026 is the figure that future quarterly reports will be measured against.
Final Word
The quarter closed with the funding facility settled and its security released, but with limited cash and a Phase 2 study that depends on new funding. The company's next updates are expected to cover the iNGENū deed, the RDTI forward funding arrangement and any agreement to fund the Phase 2 programme.






Please wait processing your request...